Jakarta, April 18, 2024. Based on the Consolidated Financial Statements of PT Enseval Putera Megatrading Tbk and its Subsidiaries (the Company) dated March 31, 2024, and for the period then ended (unaudited), the Company hereby informs that in the first quarter of 2024, the Company's Net Sales were recorded at Rp7,976.52 billion, representing a 10.18% increase compared to Net Sales in the first quarter of 2023, which was recorded at Rp7,239.58 billion.

The Company's Cost of Goods Sold in the first quarter of 2024 was recorded at Rp7,136.51 billion, an increase of 10.85% compared to Rp6,437.70 billion in the first quarter of 2023.

Thus, the Company successfully recorded a Gross Profit of IDR 840.01 billion in the first quarter of 2024, a 4.76% increase compared to the Gross Profit of IDR 801.88 billion in the first quarter of 2023.

In the first quarter of 2024, the Company's Operating Expenses were recorded at IDR 493.09 billion, consisting of Selling Expenses of IDR 436.49 billion and General and Administrative Expenses of IDR 56.60 billion, representing a 5.10% increase compared to the first quarter of 2023. Consequently, the Company recorded an Operating Profit of IDR 346.92 billion, a 4.27% increase compared to the Operating Profit of IDR 332.72 billion in the first quarter of 2023.

The Company's Profit Before Income Tax Expense in the first quarter of 2024 was recorded at IDR 354.30 billion, an increase of 3.06% compared to the same period in 2023. Other Income (Expenses) consisted of finance income of IDR 5.48 billion, finance expenses of IDR 3.89 billion, other operating income of IDR 10.12 billion, final tax expense of IDR 1.16 billion, net profit share in associated entities of IDR 2.48 billion, and other operating expenses of IDR 5.63 billion.

The Company's Income Tax Expense in the first quarter of 2024 was recorded at IDR 76.21 billion, an increase of 3.09% compared to the same period in 2023, which was IDR 73.93 billion.

As a result, the Company recorded a Current Period Profit of Rp278.09 billion in the first quarter of 2024, a 3.06% increase compared to Rp269.84 billion in the same period in 2023.

Comparing the Company's Consolidated Statements of Financial Position as of March 31, 2024 (unaudited) with the Company's Consolidated Statements of Financial Position as of December 31, 2023 (audited), the Company's Total Assets increased by 11.10%, from Rp10.96 trillion to Rp12.17 trillion. The Company's Total Liabilities increased by 25.63% from IDR 3.66 trillion as of December 31, 2023, to IDR 4.60 trillion in the first quarter of 2024. Consequently, the Company's Total Equity increased by 3.81% from IDR 7.30 trillion to IDR 7.58 trillion in the first quarter of 2024.

Performance of Each Division

The Company currently has seven divisions, consisting of Consumer Goods, Prescription Drugs, Over-the-Counter Drugs, Raw Materials for Sale, Medical Equipment, Veterinary and Livestock Drugs, and Healthcare and Transportation Services.

The details of the performance of each division within the Company are as follows:

The Consumer Goods Division contributed the largest to total Net Sales, accounting for 40.22%. In the first quarter of 2024, this division recorded net sales of IDR 3,208.10 billion, a 5.97% increase compared to the same period in 2023.

The Prescription Drugs Division contributed the second-largest revenue after the Consumer Goods Division, accounting for 32.32%. As of the first quarter of 2024, the Prescription Drugs Division recorded Net Sales of Rp2,578.26 billion, representing a 20.83% increase compared to the same period in 2023.

The Over-the-Counter Drugs Division recorded Net Sales of Rp1,208.47 billion in the first quarter of 2024, contributing 15.15% of the total revenue, a 15.46% increase compared to the same period in 2023.

The Raw Materials Division recorded Net Sales of Rp557.39 billion in the first quarter of 2024, a 10.57% decrease compared to the same period in 2023, and contributing 6.99%.

The Medical Devices Division contributed 4.95% to the first quarter of 2024, with Net Sales of Rp395.18 billion, a 6.08% increase compared to the same period in 2023.

Net Sales of the Veterinary and Livestock Medicine Division were recorded at Rp13.96 billion, a 13.82% increase compared to Rp12.27 billion in the same period in 2023. The Veterinary and Livestock Medicine Division provided contribution of 0.18% to the Company's total Net Sales.

Net Sales from the Healthcare and Transportation Services Division were recorded at IDR 15.16 billion, a 36.01% decrease compared to the same period in 2023. This division contributed 0.19%.

About Enseval

Enseval is the largest distribution company in Indonesia, having commenced distribution activities in 1973 and employing more than 4,600 employees. Enseval went public on August 1, 1994, under the name PT Enseval Putera Megatrading Tbk (IDX: EPMT). In addition to distributing Kalbe Group products, Enseval has also been trusted by other principals both domestically and internationally. The Company has an extensive distribution network with three distribution centers located in Jakarta, Cikarang, and Surabaya, 48 branches across the Indonesian archipelago, and 23 branches through its subsidiary, PT Tri Sapta Jaya. To date, the Company has 9 subsidiaries, which operate in the fields of distribution, raw materials, medical equipment, health services and transportation.